About this document
BridgeBio by Flávio Emidio is a document available to read on EtoBox.
BridgeBio Pharma is viewed as undervalued due to strong sales of its drug Attruby and a promising pipeline, with expectations of peak sales exceeding $4 billion annually. The company has three late-stage programs with blockbuster potential and is navigating a challenging biotech environment. Despite risks related to competition and market dynamics, BridgeBio
- Author
- Flávio Emidio
- Language
- EN